Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:01 2023-12-01 pm EST			5-day change	1st Jan Change
50.10 ^USD	+1.46%		+0.68%	-30.37%

Dec. 01	Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing	MT
Nov. 29	US FDA investigating safety risk of CAR-T cancer therapies	RE

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Bristol-Myers Squibb Company

Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing	Dec. 01	MT
US FDA investigating safety risk of CAR-T cancer therapies	Nov. 28	RE
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells	Nov. 28	DJ
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies	Nov. 28	MT
Sector Update: Health Care Stocks Ease Tuesday Afternoon	Nov. 28	MT
US FDA investigating safety risk of CAR-T therapies	Nov. 28	RE
Sector Update: Health Care Stocks Decline Premarket Tuesday	Nov. 28	MT
Sector Update: Health Care	Nov. 28	MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	Nov. 28	MT
Avidity Biosciences Collaborates With Bristol Myers to Advance Use of AOC in Multiple Cardiac Targets	Nov. 28	MT
Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership	Nov. 28	DJ
Avidity Biosciences, Inc. Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for Up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology	Nov. 28	CI
Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company	Nov. 27	CI
Global markets live: HP, Nordstrom, Deere, Nvidia, Broadcom...	Nov. 22
Bristol Myers Squibb Insider Bought Shares Worth $423,385, According to a Recent SEC Filing	Nov. 22	MT
US Senate Health Committee Members Ask Johnson & Johnson, Merck, Bristol-Myers Squibb CEOs to Testify on Drug Pricing	Nov. 21	MT
Johnson & Johnson, Merck, Bristol Myers Squibb Invited to Testify to Senate Health Committee on Drug Prices	Nov. 21	MT
Pharma CEOs Asked by Senate to Testify on 'Outrageously' High Prices of Prescription Drugs on Jan. 25	Nov. 21	MT
Bayer CEO says tougher cash outlook will be considered in overhaul	Nov. 21	RE
Nasdaq leads Wall Street's gains as Microsoft hits record high	Nov. 20	RE
US FDA to Miss Dec. 16 Deadline on Bristol-Myers Squib, 2seventy Bio Drug Application	Nov. 20	MT
Trending : Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA	Nov. 20	DJ
European Equities Open Week on Flat Note in Monday Trading; Bayer Shares Tumble After Asundexian Trial Ends	Nov. 20	MT
Nasdaq leads Wall St higher as Microsoft hits record high	Nov. 20	RE
Global markets live: Microsoft, Meta Platforms, Blackstone, Citigroup, Nvidia...	Nov. 20

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Company Profile

Sector

Pharmaceuticals

Calendar

2023-12-09 - American Society of Hematology Meeting - Oral Presentation #104

More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

50.10USD

Average target price

64.13USD

Spread / Average Target

+28.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-30.37%	102 B $
ELI LILLY AND COMPANY	+59.64%	525 B $
NOVO NORDISK A/S	+48.98%	454 B $
JOHNSON & JOHNSON	-10.34%	381 B $
ABBVIE INC.	-11.26%	253 B $
ROCHE HOLDING AG	-17.52%	221 B $
NOVARTIS AG	+2.14%	202 B $
ASTRAZENECA PLC	-9.09%	200 B $
PFIZER, INC.	-43.58%	163 B $
AMGEN INC.	+3.74%	146 B $

Other Pharmaceuticals